US2017266205A1PendingUtilityA1

Inducing lactation in nursing females

Individually held — no corporate assignee on recordPriority: Feb 4, 2014Filed: Apr 4, 2017Published: Sep 21, 2017
Est. expiryFeb 4, 2034(~7.5 yrs left)· nominal 20-yr term from priority
A61K 9/0014A61K 31/58A61K 9/06
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A topical cream applied to a nipple of a lactating female induces lactation. The cream comprises a base cream having from about 0.5% to about 10%, by volume, of a steroid, based upon the total volume of the cream. The preferred steroid is stanozolol. Preferably, the cream comprises at least about 1% to about 10%, by volume, of stanozolol, based on the total volume of the cream.

Claims

exact text as granted — not AI-modified
Having, thus, described the invention what is claimed is: 
     
         1 . (canceled) 
     
     
         2 . (Canceled) 
     
     
         3 . (Canceled) 
     
     
         4 . (Canceled) 
     
     
         5 . (Canceled) 
     
     
         6 . (Canceled) 
     
     
         7 . (Canceled) 
     
     
         8 . (Canceled) 
     
     
         9 . (Canceled) 
     
     
         10 . (Canceled) 
     
     
         11 . In a topical cream for inducing lactation in a female of the type which is applied to at least one nipple, the improvement which comprises:
 an effective amount of an androgen consisting essentially of an androgen-containing topical cream, the cream comprising: (a) an androgen and a blend of yohimbine HCL, caffeine, synephrine, acetyl L-carnitine, lecithin, sesamin, octopamine HO 2  and ascorbyl palmitate.   
     
     
         12 . The improvement of  claim 11  wherein the androgen is present in an amount ranging from about 1% to about 10%, by volume, based on the total volume of the cream. 
     
     
         13 . The improvement of  claim 12  which further includes an additional cream selected from the group consisting of face creams and body moisturizing creams. 
     
     
         14 . The improvement of  claim 13  wherein the androgen is selected from the group consisting of stanozolol, danazol and furazabol. 
     
     
         15 . The improvement of  claim 14  wherein the androgen is stanozolol.

Join the waitlist — get patent alerts

Track US2017266205A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.